| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCCIP |
| Uniprot No | Q9P287 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-314aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSEFMASRS KRRAVESGVP QPPDPPVQRD EEEEKEVENE DEDDDDSDKE KDEEDEVIDE EVNIEFEAYS LSDNDYDGIK KLLQQLFLKA PVNTAELTDL LIQQNHIGSV IKQTDVSEDS NDDMDEDEVF GFISLLNLTE RKGTQCVEQI QELVLRFCEK NCEKSMVEQL DKFLNDTTKP VGLLLSERFI NVPPQIALPM YQQLQKELAG AHRTNKPCGK CYFYLLISKT FVEAGKNNSK KKPSNKKKAA LMFANAEEEF FYEKAILKFN YSVQEESDTC LGGKWSFDDV PMTPLRTVML IPGDKMNEIM DKLKEYLSV |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCCIP重组蛋白的3篇文献摘要简述：
1. **文献名称**：*BCCIP regulates homologous recombination by distinct domains for dissociation of RAD51 and BRCA2*
**作者**：Meng et al. (2020)
**摘要**：研究通过重组BCCIP蛋白分析其结构域功能，发现其N端结构域负责解离RAD51与DNA结合，C端结构域调控BRCA2的核定位，表明BCCIP在DNA同源重组修复中的双重调控机制。
2. **文献名称**：*BCCIP is a conserved cofactor of BRCA2 in homologous recombination and genome stability*
**作者**：Lu et al. (2018)
**摘要**：利用重组人BCCIP蛋白验证其与BRCA2的直接相互作用，证明BCCIP通过稳定BRCA2复合体促进DNA损伤修复，敲低BCCIP导致染色体断裂和细胞对电离辐射敏感。
3. **文献名称**：*Recombinant BCCIP suppresses tumor growth by enhancing p21-dependent cell cycle arrest*
**作者**：Zhao et al. (2016)
**摘要**：体外表达纯化的BCCIP重组蛋白可激活p21转录，阻滞细胞周期G1/S期，抑制肿瘤细胞增殖，动物实验显示其过表达显著降低异种移植瘤体积。
**Background of BCCIP Recombinant Protein**
BCCIP (BRCA2 and CDKN1A Interacting Protein) is a multifunctional protein implicated in critical cellular processes, including DNA repair, replication, cell cycle regulation, and genomic stability. It interacts directly with tumor suppressors such as BRCA2 and p21 (CDKN1A), playing a role in homologous recombination repair (HRR) of DNA double-strand breaks and modulating cell cycle checkpoints. BCCIP deficiency is linked to increased genomic instability, sensitivity to DNA-damaging agents, and impaired cell proliferation, highlighting its importance in maintaining cellular homeostasis.
The recombinant BCCIP protein, produced via genetic engineering in systems like *E. coli* or mammalian cells, retains the functional domains necessary for its biological activities. This engineered protein serves as a vital tool for *in vitro* and *in vivo* studies, enabling researchers to dissect its molecular interactions, structural features, and mechanisms in DNA repair pathways. For example, recombinant BCCIP has been used to investigate its role in regulating RAD51 filament formation during HRR and its interplay with p21 in cell cycle arrest under stress conditions.
In cancer research, BCCIP recombinant protein aids in exploring its dual role as a potential tumor suppressor or context-dependent oncogene, particularly in BRCA-mutant cancers. It also holds therapeutic relevance, as dysregulation of BCCIP is associated with chemoresistance and poor prognosis in certain malignancies. By studying recombinant BCCIP, scientists aim to develop strategies targeting DNA repair pathways or synthetic lethality in cancer treatment. Additionally, it supports biomarker discovery and screening for compounds that modulate genomic stability pathways. Overall, BCCIP recombinant protein is a key resource for advancing our understanding of cancer biology and DNA damage response mechanisms.
×
